SCHEMBL4153942

SCHEMBL4153942

O=C(O)CCc1c[nH]c2c(=O)[nH]c3ccc(S(=O)(=O)Cc4c(Cl)cccc4Cl)cc3c12

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.43
GPR17 Q13304 3/20 0.42
S1PR5 Q9H228 2/20 0.38
HPGD P15428 1/20 0.35
CYP2C19 P33261 1/20 0.35
FFAR1 O14842 2/20 0.34
PARP1 P09874 1/20 0.34
SLC22A12 Q96S37 1/20 0.34
DAO P14920 1/20 0.33
S1PR1 P21453 1/20 0.33
PTPN11 Q06124 2/20 0.33
PTPN1 P18031 1/20 0.33
PTPN6 P29350 1/20 0.33
FBP1 P09467 1/20 0.32
CSNK1E P49674 1/20 0.32
CLK1 P49759 1/20 0.32
DYRK1A Q13627 1/20 0.32
DYRK2 Q92630 1/20 0.32
DYRK1B Q9Y463 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4162519 0.87 DAO (0.42) GPR17HPGDCYP2C19PARP1DAO
SCHEMBL3244677 0.85 MET (0.45) METS1PR5HPGDCYP2C19DAO
SCHEMBL4153943 0.84 MET (0.38) METCSNK1ECLK1DYRK1ADYRK2
SCHEMBL4171781 0.83 TBXAS1 (0.39) GPR17HPGDCYP2C19DAO
SCHEMBL3244679 0.83 MET (0.43) METS1PR5HPGDDAOPTPN11
SCHEMBL4155191 0.82 HPGD (0.42) GPR17HPGDCYP2C19PARP1PTPN11
SCHEMBL4157925 0.82 PNP (0.37) GPR17HPGDCYP2C19PARP1PTPN11
SCHEMBL4162915 0.81 PDGFRB (0.46) GPR17HPGDCYP2C19
SCHEMBL4170111 0.80 HPGD (0.42) GPR17HPGDCYP2C19
SCHEMBL4162699 0.80 BRD4 (0.47) GPR17

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US claimed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US claimed
US-8426437-B2 Pyrroloquinoline derivatives and their use as protein kinases inhibitors PIERRE FABRE MEDICAMENT (FR) 2013-04-23 US disclosed
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors PIERRE FABRE MEDICAMENT (FR) 2009-02-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090042876-A1 Pyrroloquinoline Derivatives And Their Use As Protein Kinases Inhibitors MAP3K1, MAP3K2, MAP3K7 MET 1215/4885GPR17 2461/4885S1PR5 2725/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.